# OnCo record intellance-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/intellance-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "intellance-1", "NCT02573324" ;
  schema:name "INTELLANCE-1"@en ;
  schema:alternateName "Intellance1"@en, "M13-813"@en ;
  schema:description "INTELLANCE-1 tested an antibody-drug conjugate that targets the EGFR amplification found in about half of glioblastomas, added to standard treatment; it did not help people live longer, and the drug was abandoned."@en ;
  schema:url <https://onco.cc/trials/intellance-1/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02573324> ;
  onco:status "negative" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:drugs <https://onco.cc/drugs/depatuxizumab-mafodotin/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:people <https://onco.cc/people/andrew-lassman/> .